CN110567861B - Kit for screening antigenic peptide with immunogenicity based on mass flow detection technology and detection method - Google Patents
Kit for screening antigenic peptide with immunogenicity based on mass flow detection technology and detection method Download PDFInfo
- Publication number
- CN110567861B CN110567861B CN201910846736.3A CN201910846736A CN110567861B CN 110567861 B CN110567861 B CN 110567861B CN 201910846736 A CN201910846736 A CN 201910846736A CN 110567861 B CN110567861 B CN 110567861B
- Authority
- CN
- China
- Prior art keywords
- solution
- liquid
- volume
- parts
- phosphate buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/302—Stain compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/305—Fixative compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention provides a kit and a detection method for screening antigenic peptides with immunogenicity based on a mass spectrometry flow detection technology, which can determine whether specific antigenic peptides have the immunogenicity of specifically activating immune cells in a sample or not by using the mass spectrometry flow detection technology aiming at the immune cells in clinical and scientific research tissue samples, improve the depth and precision of sample detection and greatly expand the flux and detection connotation of screening and analysis.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to the technical field of cell biology, in particular to a kit for screening immunogenic antigen peptides based on a mass spectrometry flow detection technology and a detection method thereof.
[ background of the invention ]
The mass flow detection technology is a technology for detecting a rare metal labeled antibody through a mass spectrometer at a single cell level and performing multi-parameter and high-throughput qualitative analysis on each cell. Compared with the traditional flow cytometry, the technology has the advantages of more detection parameters and higher signal-to-noise ratio, is the most advanced single-cell flow detection technology at present, and is more and more widely applied in the fields of clinical medicine and biological research.
T lymphocytes are important regulatory cells in the response of acquired immune response of an organism, and can carry out immune clearance on exogenous immunogenic antigen substances, so that the stability of the internal environment of the organism is maintained. When the major histocompatibility complex is bound to an antigenic peptide and transported to the surface of a cell membrane, the molecular complex can be recognized by T cells, and then the immune function of the T cells is activated. Therefore, the antigen peptide to be detected presented by the major histocompatibility complex is marked, and then the marked antigen peptide is incubated with a sample to be detected, so that whether the cells in the sample to be detected can specifically recognize the antigen peptide can be determined, and whether the antigen peptide has immunogenicity to the cells of the sample to be detected can be determined.
The tetramer formed by the major histocompatibility complex can have stronger detection precision than the monomer, so the tetramer technology has important significance in immune cell detection. The technology allows researchers to accurately detect the recognition effect of immune cells on various antigens in the pathological processes of infectious diseases, tumors, autoimmune diseases and the like.
At present, the commercial major histocompatibility complex tetramer technology can only evaluate the detection activity of the antigen peptide from the common flow detection level, has few synchronous detection parameters and low detection flux, and cannot well meet the requirements of clinical examination and scientific research of high-throughput antigen substance screening. The detection method for screening the antigenic peptide with the immunogenicity based on the mass flow detection technology can greatly meet the requirements of clinical examination and scientific research on screening the antigenic substances and fill the gap of commercial application in the field at present.
[ summary of the invention ]
The invention provides a kit for screening antigenic peptides with immunogenicity based on a mass flow detection technology, which can screen whether the antigenic peptides to be detected have immunogenicity.
The invention also provides a detection method for screening the antigenic peptide with immunogenicity based on the mass spectrometry flow detection technology.
The technical solution of the invention is as follows:
the kit for screening the immunogenic antigen peptide based on the mass spectrometry flow detection technology is characterized by comprising LD liquid, B liquid, NB liquid, W liquid, P liquid, F liquid, T liquid and BC1-BC10 liquid;
the LD liquid comprises 194Pt and RPMI 1640 basic culture medium;
the solution B is a blocking buffer solution containing human immunoglobulin, mouse immunoglobulin, rat immunoglobulin, hamster immunoglobulin, bovine serum albumin and phosphate buffer solution for flow cytometry;
the NB fluid is a tetramer complex sealant;
the W liquid is a transparent buffer liquid;
the liquid P is a fixed/transparent concentrated liquid and a fixed/transparent diluent;
the T liquid is tetramer staining incubation liquid;
the F liquid comprises formaldehyde and phosphate buffer;
the solution D comprises 191/193Ir, formaldehyde and phosphate buffer solution;
the BC1-BC10 liquid comprises phosphate buffer and any two combinations of Pd104, Pd105, Pd106, Pd108 and Pd 110.
Further, LD liquid was 1 part by volume of RPMI 1640 basic medium, 0.01 part by volume of 1mM 194Pt (201194, Fluidigm).
Further, the solution B is 0.5 to 2 parts by volume of a human immunoglobulin solution (2mg/mL), 0.5 to 2 parts by volume of a mouse immunoglobulin solution (2mg/mL), 0.5 to 2 parts by volume of a rat immunoglobulin solution (2mg/mL), 0.5 to 2 parts by volume of a hamster immunoglobulin solution (2mg/mL), 0.5 to 2 parts by mass of bovine serum albumin, 100 parts by volume of a phosphate buffer (GNM20012), and the parts by mass and the parts by volume are converted in terms of mass in mg and volume in mL, that is, 1 part by mass/1 part by volume is equal to 1 mg/mL.
Further, the NB liquid is a blocking liquid prepared from 10 to 200 parts by mass of N-ethylmaleimide (E3876, Sigma), 0.0001 to 0.001 part by mass of biotin (i.e., vitamin B7) (V900418, Sigma), and 1 part by volume of double distilled water, and the parts by mass and the parts by volume are converted in terms of mass in mg and volume in mL, that is, 1 part by mass/1 part by volume is equal to 1 mg/mL.
Further, the W solution was 1 part by volume of 10 Xpermeation solution (00-8333-56, Invitrogen) and 9 parts by volume of water.
Further, the solution P was 1 part by volume of a fixed/permeation concentrate (00-5123-43, Invitrogen) and 3 parts by volume of a fixed/permeation diluent (00-5223-56, Invitrogen).
Further, the solution T is a tetramer staining solution prepared from 0.001 to 0.01 parts by mass of a tetramer complex of a specific antigen peptide that can be customized, 0.0005 to 0.002 parts by mass of bovine serum albumin, and 1 part by volume of a phosphate buffer solution (GNM20012), wherein the parts by mass and the parts by volume are converted according to the mass in mg and the volume in mL, that is, 1 part by mass/1 part by volume is equal to 1 mg/mL.
Further, the F solution is 0.9-1.3 parts by volume of 16 wt% formaldehyde solution and 9 parts by volume of phosphate buffer solution (GNM 20012).
Further, the D liquid was 0.005 part by volume of Cell-IDTMIntercalator-Ir (201192B, Fluidigm), 0.9-1.3 parts by volume of 16 wt% formaldehyde solution, 9 parts by volume of phosphate buffer (GNM 20012).
Further, the air conditioner is provided with a fan,
BC1 solution contains 1 part by volume of Pd104 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd105 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC2 solution contains 1 volume part of Pd106 (1.5-2. mu.M, Fluidigm), 1 volume part of Pd108 (1.5-2. mu.M, Fluidigm), 100 volume parts of phosphate buffer (GNM 20012);
BC3 solution contains 1 part by volume of Pd105 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd110 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC4 solution contains 1 part by volume of Pd104 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd106 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC5 solution contains 1 part by volume of Pd105 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd108 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC6 solution contains 1 part by volume of Pd106 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd110 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC7 solution contains 1 volume part of Pd104 (1.5-2. mu.M, Fluidigm), 1 volume part of Pd108 (1.5-2. mu.M, Fluidigm), 100 volume parts of phosphate buffer (GNM 20012);
BC8 solution contains 1 part by volume of Pd105 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd106 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC9 solution contains 1 part by volume of Pd104 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd110 (1.5-2. mu.M, Fluidigm), 100 parts by volume of phosphate buffer (GNM 20012);
BC10 solution contained 1 part by volume of Pd108 (1.5-2. mu.M, Fluidigm), 1 part by volume of Pd110 (1.5-2. mu.M, Fluidigm), and 100 parts by volume of phosphate buffer (GNM 20012).
Wherein, each sample to be detected selects one of BC (1-10) solution for dyeing, different BC solutions are required to be selected for different samples, and at most 10 different samples to be detected can be detected simultaneously. Parts by volume are measured in mL.
Further, LD solution, B solution, NB solution, W solution, P solution, F solution, T solution, and BC1-BC10 solution were prepared and then stored at 2-8 ℃.
The antigen peptide tetramer complex of the kit has specificity on the identification of cells capable of activating immunocompetence, and the tetramer assembled by the antigen peptide incapable of activating the immunocompetence of sample cells cannot identify the sample cells.
The detection method for screening the immunogenic antigen peptide based on the mass spectrometry flow detection technology is characterized in that the kit is used, and comprises the following steps:
step one, preparing single cell suspension:
collecting digestive cells, and gently blowing and beating the digestive cells by using a pipette gun to obtain a single cell suspension;
step two, determining cell death and cell viability:
adding 1mL LD solution prepared from 1mL RPMI 1640 basic culture medium and 0.01mL 1mM 194Pt (201194, Fluidigm), gently blowing the cell sediment at the bottom of the tube to resuspend the cells, and incubating in a cell culture box at 37 deg.C, preferably for 5 min;
step three, sealing:
add 50. mu.L of liquid B to each sample to resuspend the cell pellet and incubate on ice, preferably for 20 minutes; the solution B is prepared from 0.5-2mL human immunoglobulin solution (2mg/mL), 0.5-2mL mouse immunoglobulin solution (2mg/mL), 0.5-2mL rat immunoglobulin solution (2mg/mL), 0.5-2mL hamster immunoglobulin solution (2mg/mL), 0.5-2mg bovine serum albumin, and 100mL phosphate buffer (GNM 20012);
step four, blocking the tetramer complex:
adding 50mL of the solution T to 50mL of the solution NB to obtain a final volume of 100. mu.L; after mixing, the mixture is incubated at room temperature for a certain period of time (preferably 10 minutes). Wherein the T liquid is tetramer staining incubation liquid prepared by 0.001-0.01mg of customizable tetramer compound of specific antigen peptide, 0.0005-0.002mg of bovine serum albumin and 1mL of phosphate buffer solution; NB liquid is prepared from 10-200mg of N-ethylmaleimide (E3876, Sigma), 0.0001-0.001mg of biotin (V900418, Sigma) and 1mL of double distilled water;
step five, dyeing the tetramer compound:
adding a mixed solution of 100 mu LT solution and NB solution into each cell sample, and incubating for a certain time (preferably 1 hour) at room temperature;
step six, staining the cell surface with antibodies:
adding bovine serum albumin solution (0.5-2% by mass/volume, dissolved in phosphate buffer) into the cell surface antibody at a proper dilution ratio, mixing with the sample, and incubating on ice for a certain time, preferably 30 minutes;
step seven, transparent:
adding 100 μ L of P solution to each cell sample to resuspend the cells, wherein the P solution is prepared from 1mL of fixed/permeable concentrated solution (00-5123-43, Invitrogen) and 3mL of fixed/permeable diluted solution (00-5223-56, Invitrogen), and incubating at room temperature for a certain time, preferably 30 minutes;
step eight, staining intracellular antibodies:
preparing intracellular antibody staining solution, adding an antibody to 100 mu L of W solution according to a proper proportion, adding the mixture into cell sediment, uniformly mixing, and incubating on ice for a certain time, preferably 30 minutes; w solution was prepared from 1mL of 10X permeant solution (00-8333-56, Invitrogen), 9mL of water;
step nine, cell fixation:
adding 1mL of F solution into each EP tube, blowing and sucking by a pipette, uniformly mixing and resuspending cells, and incubating at room temperature for a certain time, preferably 10 minutes; f II solution is composed of 0.9-1.3mL of 0.16mg/mL formaldehyde solution and 9mL of phosphate buffer solution (GNM 20012);
step ten, DNA staining and fixing:
adding 1mL of solution D into each EP tube, blowing and sucking by a pipette, uniformly mixing, and standing overnight in a refrigerator at 4 ℃; solution D was composed of 0.005mL of Cell-IDTMIntercalator-Ir (201192B, Fluidigm), 0.9-1.3mL of 0.16mg/mL formaldehyde solution and 9mL of phosphate buffer solution (GNM 20012);
step eleven, labeling cell barcodes:
adding 100 μ L of a BC solution containing phosphate buffer solution and any two combinations of Pd104, Pd105, Pd106, Pd108 and Pd110 into the sample cells, resuspending the cells, and incubating on ice for a certain time, preferably 30 minutes;
step twelve, rinsing and computer detection:
after rinsing the cells with double distilled water, transferring the cells to a flow tube, counting the cells, and detecting the cells on a machine.
The invention has the following overall beneficial effects:
the invention carries out accurate immune typing on cell populations through a mass flow cytometry technology, carries out comprehensive analysis on an intracellular signal conduction network, analyzes functional connection among cell subsets, and is used for high-throughput multi-parameter detection of a large number of samples by combining with an MHC-Tetramer technology for T cell detection, sorting, activation and amplification of antigen specificity, thereby being used for screening T cell recognition epitopes and detecting specific T cells, realizing specific, effective and high-throughput screening of immunogenic antigen peptides of immune cells in an activated tissue organ sample at a single cell level, greatly improving the depth and precision of sample detection, and greatly expanding the flux and detection connotation of screening and analysis.
[ description of the drawings ]
FIG. 1 is a schematic flow chart of a detection method for screening immunogenic antigenic peptides based on a mass spectrometric detection technique;
FIG. 2 shows the flow detection results of the antigen peptide A tetramer complex and the antigen peptide B tetramer complex of the negative control sample;
FIG. 3 shows the results of antigenic peptide detection using the kit of the present invention;
FIG. 4 shows the results of detection of intracellular signals while detecting A antigen peptide cells using the kit of the present invention.
[ detailed description ] embodiments
The present invention will be described in further detail with reference to the following examples, but the present invention is not limited to the following examples.
The following examples are not intended to limit the scope of the present invention, nor are the steps described to limit the order in which they are performed, i.e., to aqueous solutions, unless otherwise specified, concentrations differing by unit from one type of concentration, e.g., "mg/mL" to indicate the ratio of solute mass to solution volume, and so on. Modifications of the invention which are obvious to those skilled in the art in view of the prior art are also within the scope of the invention as claimed.
The kit for screening the immunogenic antigen peptide based on the mass spectrometry flow detection technology is characterized by comprising LD liquid, B liquid, NB liquid, W liquid, P liquid, F liquid, T liquid and BC1-BC10 liquid;
the LD liquid comprises 194Pt and RPMI 1640 basic culture medium;
the solution B is a blocking buffer solution containing human immunoglobulin, mouse immunoglobulin, rat immunoglobulin, hamster immunoglobulin, bovine serum albumin and phosphate buffer solution for flow cytometry;
the NB fluid is a tetramer complex sealant;
the W liquid is a transparent buffer liquid;
the liquid P is a fixed/transparent concentrated liquid and a fixed/transparent diluent;
the T liquid is tetramer staining incubation liquid;
the F liquid comprises formaldehyde and phosphate buffer;
the solution D comprises 191/193Ir, formaldehyde and phosphate buffer solution;
the BC1-BC10 liquid comprises phosphate buffer and any two combinations of Pd104, Pd105, Pd106, Pd108 and Pd 110.
Based on the kit for screening the immunogenic antigen peptide by the mass flow detection technology, CD45(Biolegend) and Ki67(eBiosciences) are additionally used for detecting extracellular and intracellular target proteins of sample cells, and the specific steps are as follows:
step one, preparing a sample single cell suspension:
1) collecting single cell suspension obtained after digestion, counting cells, wherein the sample cell tested in the example is mouse m33 cell, and dividing the sample cell into a control group and a staining group for experiment;
2) get 107Unicellular, centrifugate 400g/5min at room temperature, abandon the supernatant;
3) at 107Adding a serum-free RPMI 1640 culture medium preheated at 37 ℃ into the/mL cell density, centrifuging at room temperature for 400g/5min, and discarding the supernatant;
step two, determining cell death and cell viability:
4) adding 1mL LD solution prepared from 1mL RPMI 1640 basic culture medium and 0.01mL 1mM 194Pt (201194, Fluidigm), gently blowing the cell precipitate at the bottom of the tube to resuspend the cells, and incubating in a cell culture box at 37 ℃ for 5 min;
5) adding 5mL of RPMI 1640 medium containing serum preheated at 37 ℃, centrifuging at room temperature for 400g/5min, and discarding the supernatant;
step three, sealing:
6) add 50. mu.L of liquid B to each sample to resuspend the cell pellet and transfer to a clean 1.5mL EP tube, label, incubate for 20 minutes on ice; the solution B is prepared from 0.5-2mL human immunoglobulin solution (2mg/mL), 0.5-2mL mouse immunoglobulin solution (2mg/mL), 0.5-2mL rat immunoglobulin solution (2mg/mL), 0.5-2mL hamster immunoglobulin solution (2mg/mL), 0.5-2mg bovine serum albumin, and 100mL phosphate buffer (GNM 20012);
step four, blocking the tetramer complex:
7) preparing a tetramer complex closed mixed solution during the incubation period of the cell sample on ice, adding NB solution into T solution to make the final volume 100 mu L, and incubating at room temperature for 10min after uniform mixing; the solution T is a tetramer staining solution prepared from 0.001-0.01 parts by mass of a customizable tetramer compound of a specific antigen peptide, 0.0005-0.002 parts by mass of bovine serum albumin and 1 part by volume of a phosphate buffer solution; NB liquid is prepared by 10-200 parts by mass of N-ethylmaleimide (E3876, Sigma), 0.001-0.01 part by mass of biotin (V900418, Sigma) and 1 part by volume of double distilled water;
step five, dyeing the tetramer compound:
8) adding 1mL of bovine serum albumin solution (0.5% by mass/volume in phosphate buffer) into each EP tube to wash the cells, centrifuging at 4 ℃ for 800g/5min, and removing the supernatant;
9) adding a mixed solution of 100 mu LT solution and NB solution into each EP tube, and incubating for 60min at room temperature;
step six, staining the cell surface with antibodies:
10) adding 1mL of bovine serum albumin solution (0.5% by mass/volume in phosphate buffer) into each EP tube to wash the cells, centrifuging at 4 ℃ for 800g/5min, and removing the supernatant;
11) preparing a mixed solution of cell surface marker antibodies, adding an antibody CD45(1:100 volume ratio) to a bovine serum albumin solution (0.5-2% by mass volume ratio, dissolved in a phosphate buffer solution) according to a proper dilution ratio, adding 100 mu L of the mixed solution to each sample, and preparing 300 mu L of the mixed solution;
12) adding 100 mu L of cell surface marker antibody mixed solution into each EP tube, uniformly mixing, and incubating on ice for 30 min;
step seven, transparent:
13) adding 1mL of W solution into each EP tube, centrifuging at 4 ℃ for 800g/5min, and removing supernatant;
14) adding 100 μ L of P solution into each cell sample, resuspending cells, preparing two horizontal lines from 1mL of fixed/transparent concentrated solution (00-5123-43, Invitrogen) and 3mL of fixed/transparent diluted solution (00-5223-56, Invitrogen), and incubating at room temperature for 30 min;
15) adding 1mL of W solution into each EP tube, centrifuging at 4 ℃ for 800g/5min, and removing the supernatant for the first time;
16) adding 1mL of W solution into each EP tube, centrifuging at 4 ℃ for 800g/5min, and discarding the supernatant for the second time;
step eight, staining intracellular antibodies:
17) preparing intracellular antibody staining solution, adding an antibody Ki67(1:200 volume ratio) to 100 μ L of W solution in a proper proportion, adding into cell precipitate, mixing, and incubating on ice for 30 min; w solution was prepared from 1mL of 10X permeant solution (00-8333-56, Invitrogen), 9mL of water;
18) adding 1mL of P solution into each EP tube to stop washing cells, wherein the P solution is prepared from 1mL of fixed/transparent concentrated solution (00-5123-43, Invitrogen) and 3mL of fixed/transparent diluent (00-5223-56, Invitrogen), centrifuging at 4 ℃ for 800g/5min, and discarding the supernatant;
19) adding 1mL of bovine serum albumin solution (0.5% by mass/volume in phosphate buffer) into each EP tube to wash the cells, centrifuging at 4 ℃ for 800g/5min, and removing the supernatant;
step nine, cell fixation:
20) adding 1mL of F solution into each EP tube, blowing and sucking by a pipette, uniformly mixing and resuspending cells, and incubating for 10min at room temperature; the F solution is composed of 0.9-1.3mL of 16% formaldehyde solution and 9mL of phosphate buffer solution (GNM 20012);
21) centrifuging at 4 deg.C for 800g/5min, and removing supernatant;
step ten, DNA staining and fixing:
22) adding 1mL of solution D into each EP tube, blowing and sucking by a pipette, uniformly mixing, and standing overnight in a refrigerator at 4 ℃; liquid D was prepared from 0.0005mL of Cell-IDTM Intercalator-Ir(201192B，Fluidigm)、0.09-0.13mL of 16% (mass to volume ratio, mg/mL) formaldehyde solution and 0.9mL of phosphate buffer solution (GNM 20012);
step eleven, labeling cell barcodes:
23) taking out the cell sample from a refrigerator at 4 ℃, centrifuging at 4 ℃ for 800g/5min, and removing the supernatant;
24) adding 1mL of phosphate buffer solution (GNM20012) into each EP tube, centrifuging at 4 ℃ for 800g/5min, and removing supernatant;
25) adding 100 μ L of BC1 solution into the sample cells, wherein BC1 solution contains 1mL of LPd104(1.5-2 μ M, Fluidigm), 1mL of Pd105(1.5-2 μ M, Fluidigm) and 100mL of phosphate buffer (GNM20012), resuspending the cells, and incubating on ice for 30 min;
26) adding 1mL of bovine serum albumin solution (0.5-2 parts by mass of bovine serum albumin, 100 parts by volume of phosphate buffer GNM20012, wherein the parts by mass are mg and the parts by volume are mL) into each EP tube, centrifuging at 4 ℃ for 800g/5min, and removing supernatant;
27) adding 1mL of water into each EP tube to resuspend cells, centrifuging at 4 ℃ for 800g/5min, and discarding the supernatant;
28) preparing a flow pipe with a filter membrane filter head, and marking the pipe wall;
thirteen steps of rinsing and computer detection:
29) after 1mL of water was added to each EP tube to resuspend the cells, the cell suspension was aspirated by pipette gun through the filter head filter and transferred to the corresponding flow tube. Adding 1mL of water again to clean the wall of the EP tube for a plurality of times, absorbing the cleaning solution by using a pipette gun, filtering the same flow tube filter membrane and putting the same flow tube filter membrane into the same flow tube;
30) centrifuging at 4 deg.C for 800g/5min, and removing supernatant;
31) after 1mL of water was added to each flow tube to resuspend the cells, 10. mu.L of each was counted.
32) According to the cell counting result, the cells of the control group and the treated group with the same cell number are taken, after mixing, the cell sample is washed for a plurality of times by water, a proper amount of balance magnetic beads are added, the detection is carried out on a Helios mass spectrometer (Fluidigm) machine, and the two groups of data are processed and analyzed.
We assembled tetrameric complexes using specific antigenic peptide a capable of binding to m33 cell surface T cell receptors, and verified whether the assembled specific antigenic peptide tetrameric complexes could recognize m33 cell surface T cell receptors using mass spectrometry flow techniques. Meanwhile, we selected antigenic peptide B weakly bound to m33 cell surface T cell receptor to assemble into tetrameric complexes as a negative control sample. The flow detection results of the antigen peptide A tetramer complex and the antigen peptide B tetramer complex of the negative control sample are shown in FIG. 2. After the kit for screening the immunogenic antigen peptides based on the mass flow detection technology is used for detecting the antigen peptides, cell populations capable of specifically identifying the A antigen peptides in m33 cells can be successfully detected, and an effective detection result similar to flow cytometry detection is obtained, wherein the detection result is shown in figure 3. In addition, the kit for screening the antigenic peptide with immunogenicity based on the mass spectrometry flow detection technology can simultaneously detect the intracellular signal Ki67 of the sample cell, and the blank staining group has no obvious difference from the staining effect of the A antigenic peptide tetramer, which indicates that the staining effect of the tetramer does not influence the intracellular staining effect of the sample cell, as shown in FIG. 4. The existing using method allows the signal path detection kit based on the mass flow detection technology or the cell cycle detection kit based on the mass flow detection technology and the detection method to be utilized to simultaneously detect the signal path and the cell cycle regulation and control change in immune cells activated by the specific antigen peptide while detecting whether cells responding to the specific antigen peptide to activate the immune reaction exist in sample cells, thereby expanding the application connotation of the kit.
Claims (4)
1. The kit for screening the immunogenic antigen peptide based on the mass spectrometry flow detection technology is characterized by comprising LD liquid, B liquid, NB liquid, T liquid, P liquid, W liquid, F liquid, D liquid, BC1 liquid, BC2 liquid, BC3 liquid, BC4 liquid, BC5 liquid, BC6 liquid, BC7 liquid, BC8 liquid, BC9 liquid and BC10 liquid;
the LD liquid comprises 194Pt and RPMI 1640 basic culture medium;
the solution B is a blocking buffer solution containing human immunoglobulin, mouse immunoglobulin, rat immunoglobulin, hamster immunoglobulin, bovine serum albumin and phosphate buffer solution for flow cytometry;
the NB liquid is a tetramer compound sealant and is prepared from 10-200 parts by mass of N-ethylmaleimide, 0.0001-0.001 part by mass of biotin and 1 part by volume of double distilled water;
the T liquid is tetramer staining incubation liquid and is prepared by 0.001-0.01 parts by mass of customizable tetramer compound of specific antigen peptide, 0.0005-0.002 parts by mass of bovine serum albumin and 1 part by volume of phosphate buffer solution; the tetramer complex of the specific antigen peptide in the T liquid is a tetramer complex consisting of the specific antigen peptide capable of binding to a T cell receptor on the surface of the m33 cell;
the liquid P is a fixed permeable liquid;
the W liquid is a transparent buffer liquid;
the F solution is a cell fixing solution containing formaldehyde and a phosphate buffer solution;
the D solution is 0.005 volume part of Cell-IDTMIntercalator-Ir, 0.9-1.3 parts by volume of 16 wt% formaldehyde solution and 9 parts by volume of phosphate buffer solution;
the BC1 liquid contains 1 volume part of 1.5-2 mu M Pd104, 1 volume part of 1.5-2 mu M Pd105 and 100 volume parts of phosphate buffer;
the BC2 liquid contains 1 volume part of 1.5-2 mu M Pd106, 1 volume part of 1.5-2 mu M Pd108 and 100 volume parts of phosphate buffer;
the BC3 liquid contains 1 volume part of 1.5-2 mu M Pd105, 1 volume part of 1.5-2 mu M Pd110 and 100 volume parts of phosphate buffer;
the BC4 liquid contains 1 volume part of 1.5-2 mu M Pd104, 1 volume part of 1.5-2 mu M Pd106 and 100 volume parts of phosphate buffer;
the BC5 liquid contains 1 volume part of 1.5-2 mu M Pd105, 1 volume part of 1.5-2 mu M Pd108 and 100 volume parts of phosphate buffer;
the BC6 liquid contains 1 volume part of 1.5-2 mu M Pd106, 1 volume part of 1.5-2 mu M Pd110 and 100 volume parts of phosphate buffer;
the BC7 liquid contains 1 volume part of 1.5-2 mu M Pd104, 1 volume part of 1.5-2 mu M Pd108 and 100 volume parts of phosphate buffer;
the BC8 liquid contains 1 volume part of 1.5-2 mu M Pd105, 1 volume part of 1.5-2 mu M Pd106 and 100 volume parts of phosphate buffer;
the BC9 liquid contains 1 volume part of 1.5-2 mu M Pd104, 1 volume part of 1.5-2 mu M Pd110 and 100 volume parts of phosphate buffer;
the BC10 liquid contains 1 volume part of 1.5-2 mu M Pd108, 1 volume part of 1.5-2 mu M Pd110 and 100 volume parts of phosphate buffer;
the parts by mass and parts by volume are converted into mg-based mass and mL-based volume.
2. The kit for screening antigenic peptides with immunogenicity based on mass spectrometric detection technique according to claim 1,
the LD liquid is 1 volume part of RPMI 1640 basic culture medium and 0.01 volume part of 1mM 194 Pt;
the solution B comprises 0.5-2 parts by volume of a human immunoglobulin solution with the concentration of 2mg/mL, 0.5-2 parts by volume of a mouse immunoglobulin solution with the concentration of 2mg/mL, 0.5-2 parts by volume of a rat immunoglobulin solution with the concentration of 2mg/mL, 0.5-2 parts by volume of a hamster immunoglobulin solution with the concentration of 2mg/mL, 0.5-2 parts by mass of bovine serum albumin and 100 parts by volume of a phosphate buffer solution;
the liquid P is 1 volume part of fixed transparent concentrated liquid and 3 volume parts of fixed transparent diluent;
the W liquid is 1 volume part of 10 multiplied permeable liquid and 9 volume parts of water;
the F solution is 0.9-1.3 volume parts of 16 wt% formaldehyde solution and 9 volume parts of phosphate buffer solution.
3. The kit for screening immunogenic antigen peptides based on mass spectrometry flow detection technology of claim 1 or 2, wherein the preparation of LD solution, B solution, NB solution, W solution, P solution, F solution, T solution, BC1 solution, BC2 solution, BC3 solution, BC4 solution, BC5 solution, BC6 solution, BC7 solution, BC8 solution, BC9 solution and BC10 solution is completed and then stored at 2-8 ℃.
4. Detection method for screening antigenic peptides with immunogenicity based on mass spectrometric detection techniques, characterized in that the use of a kit according to any one of claims 1 to 3 comprises the following steps:
step one, preparing single cell suspension:
collecting digestive cells, and gently blowing and beating the digestive cells by using a pipette gun to obtain a single cell suspension;
step two, determining cell death and cell viability:
adding 1mL of LD liquid, wherein the LD liquid is prepared by RPMI 1640 basic culture medium and 194Pt, gently blowing and beating cell sediment at the bottom of a tube to resuspend cells, and incubating in a cell culture box at 37 ℃;
step three, sealing:
add 50. mu.L of liquid B to each sample to resuspend the cell pellet and incubate on ice; the solution B is prepared from a human immunoglobulin solution with the concentration of 2mg/mL, a mouse immunoglobulin solution with the concentration of 2mg/mL, a rat immunoglobulin solution with the concentration of 2mg/mL, a hamster immunoglobulin solution with the concentration of 2mg/mL, bovine serum albumin and a phosphate buffer solution;
step four, blocking the tetramer complex:
adding NB solution into the T solution to make the final volume 100 μ L, mixing uniformly, and incubating at room temperature; the T liquid is a tetramer staining liquid prepared from a customizable tetramer compound of specific antigen peptide, bovine serum albumin and a phosphate buffer solution; the NB liquid is prepared from N-ethylmaleimide, biotin and double distilled water;
step five, dyeing the tetramer compound:
adding a mixed solution of 100 mu L T liquid and NB liquid into each cell sample, and incubating at room temperature;
step six, staining the cell surface with antibodies:
adding a bovine serum albumin solution which is dissolved in a phosphate buffer solution and has the mass volume ratio of 0.5-2 mg/mL into the cell surface antibody according to a proper dilution ratio, uniformly mixing the cell surface antibody with the sample, and incubating the mixture on ice;
step seven, transparent:
adding 100 mu L of P solution into each cell sample to resuspend the cells, preparing the P solution by 1mL of fixed transparent concentrated solution and 3mL of fixed transparent diluent, and incubating at room temperature;
step eight, staining intracellular antibodies:
preparing intracellular antibody staining solution, adding an antibody to 100 mu L of W solution according to a proper proportion, adding the mixture into cell sediment, uniformly mixing, and incubating on ice; the W liquid is prepared from 1mL of 10 × permeable liquid and 9mL of water;
step nine, cell fixation:
adding 1mL of F solution into each EP tube, blowing and sucking by a pipette, uniformly mixing and resuspending cells, and incubating at room temperature; the solution F comprises 0.9-1.3mL of 16 wt% formaldehyde solution and 9mL of phosphate buffer solution;
step ten, DNA staining and fixing:
adding 1mL of solution D into each EP tube, blowing and sucking by a pipette, uniformly mixing, and standing overnight in a refrigerator at 4 ℃; liquid D was prepared from 0.0005mL of Cell-IDTMIntercalator-Ir, 0.09-0.13mL of formaldehyde solution with the mass volume ratio of 16 wt% and 0.9mL of phosphate buffer solution;
step eleven, labeling cell barcodes:
adding 100 mu L of BC1 solution, BC2 solution, BC3 solution, BC4 solution, BC5 solution, BC6 solution, BC7 solution, BC8 solution, BC9 solution or BC10 solution into the sample cells, resuspending the cells, and placing the cells on ice for incubation;
step twelve, rinsing and computer detection:
and (4) rinsing the cells with double distilled water, transferring the cells to a flow tube, counting, and detecting on a machine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910846736.3A CN110567861B (en) | 2019-09-09 | 2019-09-09 | Kit for screening antigenic peptide with immunogenicity based on mass flow detection technology and detection method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910846736.3A CN110567861B (en) | 2019-09-09 | 2019-09-09 | Kit for screening antigenic peptide with immunogenicity based on mass flow detection technology and detection method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110567861A CN110567861A (en) | 2019-12-13 |
| CN110567861B true CN110567861B (en) | 2021-12-21 |
Family
ID=68778312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910846736.3A Active CN110567861B (en) | 2019-09-09 | 2019-09-09 | Kit for screening antigenic peptide with immunogenicity based on mass flow detection technology and detection method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110567861B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111024947A (en) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | Candida albicans fluorescence immunochromatography assay kit and preparation method thereof |
| CN111189761A (en) * | 2020-01-10 | 2020-05-22 | 浙江普罗亭健康科技有限公司 | Cell signal channel detection kit based on mass spectrometry flow technology and detection method |
| CN114113278B (en) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | Epitope positioning method of in-vitro diagnostic reagent antibody based on mass spectrum |
| CN116296702B (en) * | 2023-04-10 | 2023-12-29 | 杭州普罗亭医学检验实验室有限公司 | Dead-living dye capable of customizing detection channel based on mass spectrometry detection technology and preparation method and application thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105981026A (en) * | 2014-02-06 | 2016-09-28 | 因姆内克斯普雷斯私人有限公司 | Biomarker signature method, and apparatus and kits therefor |
| CN106645677A (en) * | 2016-11-15 | 2017-05-10 | 恒瑞源正（深圳）生物科技有限公司 | Method and kit for in vitro detection of tumor neoantigen specificity T cells and tumor vaccine |
| CN107024591A (en) * | 2017-05-02 | 2017-08-08 | 浙江星博生物科技股份有限公司 | Flow cytometer detection reagent for detecting InhibinB contents and its preparation method and application |
| CN107636162A (en) * | 2015-06-01 | 2018-01-26 | 加利福尼亚技术学院 | Compositions and methods for screening T cells with antigens against specific populations |
| CN107796748A (en) * | 2017-09-28 | 2018-03-13 | 上海交通大学 | A kind of detection method for unicellular mass spectrum flow cytometry |
| CN108064236A (en) * | 2015-03-31 | 2018-05-22 | 免疫医疗有限公司 | Novel IL33 forms, mutant forms of IL33, antibodies, assays and methods of use thereof |
| CN108165537A (en) * | 2010-04-27 | 2018-06-15 | Atyr医药公司 | Treatment relevant with the protein fragments of Threonyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found |
| US10168328B2 (en) * | 2015-07-22 | 2019-01-01 | Roche Sequencing Solutions, Inc. | Identification of antigen epitopes and immune sequences recognizing the antigens |
| CN109323908A (en) * | 2018-10-10 | 2019-02-12 | 浙江大学 | A detection method for mass spectrometry |
| CN109425743A (en) * | 2017-08-29 | 2019-03-05 | 北京大学 | Detect the microballoon double-antibody sandwich detection method and kit of solubility FAM19A4 albumen |
| CN110187091A (en) * | 2019-04-18 | 2019-08-30 | 浙江大学 | A kind of high-throughput 3D electric cell-substrate impedance sensor and detection method for screening anti-tumor medicine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8383081B2 (en) * | 1999-05-10 | 2013-02-26 | Immunomedics, Inc. | Anti-CD74 immunoconjugates and methods of use |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
-
2019
- 2019-09-09 CN CN201910846736.3A patent/CN110567861B/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108165537A (en) * | 2010-04-27 | 2018-06-15 | Atyr医药公司 | Treatment relevant with the protein fragments of Threonyl-tRNA synthetase, diagnosis and the innovation of antibody compositions are found |
| CN105981026A (en) * | 2014-02-06 | 2016-09-28 | 因姆内克斯普雷斯私人有限公司 | Biomarker signature method, and apparatus and kits therefor |
| CN108064236A (en) * | 2015-03-31 | 2018-05-22 | 免疫医疗有限公司 | Novel IL33 forms, mutant forms of IL33, antibodies, assays and methods of use thereof |
| CN107636162A (en) * | 2015-06-01 | 2018-01-26 | 加利福尼亚技术学院 | Compositions and methods for screening T cells with antigens against specific populations |
| US10168328B2 (en) * | 2015-07-22 | 2019-01-01 | Roche Sequencing Solutions, Inc. | Identification of antigen epitopes and immune sequences recognizing the antigens |
| CN106645677A (en) * | 2016-11-15 | 2017-05-10 | 恒瑞源正（深圳）生物科技有限公司 | Method and kit for in vitro detection of tumor neoantigen specificity T cells and tumor vaccine |
| CN107024591A (en) * | 2017-05-02 | 2017-08-08 | 浙江星博生物科技股份有限公司 | Flow cytometer detection reagent for detecting InhibinB contents and its preparation method and application |
| CN109425743A (en) * | 2017-08-29 | 2019-03-05 | 北京大学 | Detect the microballoon double-antibody sandwich detection method and kit of solubility FAM19A4 albumen |
| CN107796748A (en) * | 2017-09-28 | 2018-03-13 | 上海交通大学 | A kind of detection method for unicellular mass spectrum flow cytometry |
| CN109323908A (en) * | 2018-10-10 | 2019-02-12 | 浙江大学 | A detection method for mass spectrometry |
| CN110187091A (en) * | 2019-04-18 | 2019-08-30 | 浙江大学 | A kind of high-throughput 3D electric cell-substrate impedance sensor and detection method for screening anti-tumor medicine |
Non-Patent Citations (3)
| Title |
|---|
| "Linking T-cell receptor sequence to functional phenotype at the single-cell level";Arnold Han 等;《Nature Biotechnology》;20141231;第32卷;第684–692页 * |
| "MHC四聚体技术的应用研究进展";熊玉琪 等;《临床检验杂志》;20160731;第34卷(第7期);第589-591页 * |
| "主要组织相容性复合体-肽四聚体技术及其在定量检测抗原特异性T细胞中的应用";虞伟 等;《医学研究生学报》;20080630;第21卷(第6期);第643-647页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110567861A (en) | 2019-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110567861B (en) | Kit for screening antigenic peptide with immunogenicity based on mass flow detection technology and detection method | |
| CN110608991B (en) | Cell cycle detection kit based on mass flow detection technology and detection method | |
| CN101587043B (en) | Integrated method for enriching and detecting rare cell in biological fluid sample | |
| US20090246796A1 (en) | Isolation and enumeration of cells from a complex sample matrix | |
| CN103033619A (en) | Protein chip reagent kit and method for comprehensively detecting lung cancer marker | |
| EP1969373A2 (en) | Multiplexed detection of anti-red cell alloantibodies | |
| CN103344772B (en) | Novel Miltenberger blood group antibody detecting method | |
| CN104360087A (en) | Method for detecting Miltenberger blood group antibody | |
| CN112946264A (en) | Sample pretreatment method and immune cell detection method for flow cytometry | |
| CN111189761A (en) | Cell signal channel detection kit based on mass spectrometry flow technology and detection method | |
| CN110346557B (en) | Detection kit | |
| CN115166252A (en) | Lymphocyte subgroup classification and quantitative detection kit, detection method and application thereof | |
| CN111474347A (en) | Novel coronavirus detection kit, preparation method and detection method thereof | |
| WO2021036105A1 (en) | Combined formulation kit for analyzing phenotype and function of cd1c+ dendritic cell subset and use thereof | |
| CN112098646B (en) | Kit for quantitatively detecting lymphocyte subpopulation and detection method thereof | |
| CN110174519B (en) | A kind of pool-checking red blood cell blood group irregular antibody detection kit based on solid-phase agglutination technology and preparation method | |
| CN102313813B (en) | Integration method for enriching and detecting rare cells from biological fluid samples | |
| CN111707825A (en) | Kit for combined detection of tumor markers MCT1 and MCT4, and preparation method and application thereof | |
| US9632086B2 (en) | Method and kit for determining-antibody sensitivity and clone cell strain | |
| US20080206790A1 (en) | Assay for determining the presence or amount of newly synthesized antibodies | |
| CN117054200B (en) | TUNEL special fixation permeabilization agent for flow cytometry analysis of apoptotic cells and its preparation method and application | |
| CN115656154B (en) | Anti-RNP antibody chemiluminescence detection kit based on recombinant RNP multiple antigens | |
| US20070292839A1 (en) | Assay | |
| CN212410606U (en) | Platelet antibody specificity flow detection kit | |
| US12360112B2 (en) | Method for identification of viruses and diagnostic kit using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kit and detection method for screening immunogenic antigen peptides based on mass spectrometry flow cytometry technology Granted publication date: 20211221 Pledgee: Guotou Taikang Trust Co.,Ltd. Pledgor: ZHEJIANG PLTTECH HEALTH TECHNOLOGY CO.,LTD. Registration number: Y2024980011422 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20211221 Pledgee: Guotou Taikang Trust Co.,Ltd. Pledgor: ZHEJIANG PLTTECH HEALTH TECHNOLOGY CO.,LTD. Registration number: Y2024980011422 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A kit and detection method for screening immunogenic antigen peptides based on mass spectrometry flow cytometry technology Granted publication date: 20211221 Pledgee: Kunlun Trust Co.,Ltd. Pledgor: ZHEJIANG PLTTECH HEALTH TECHNOLOGY CO.,LTD. Registration number: Y2025980019918 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |